Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity. This is further to the company?s previous intimation of 27 March 2024, informing that approval was received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva. The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
307 INR | +4.05% | -1.25% | +22.97% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
307 INR | +4.05% | -1.25% | 4.22B | ||
3.34 RON | +2.45% | +2.45% | 504M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.97% | 4.22B | |
+10.44% | 107B | |
+0.82% | 106B | |
+8.59% | 23.47B | |
-13.89% | 21.9B | |
-6.03% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- BIOCON Stock
- News Biocon Limited
- Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution